Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Karen A GelmonWendy R Parulekar

Abstract

The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown. The MA.31 trial compared a combination of first-line anti-HER2 therapy (lapatinib or trastuzumab) and taxane therapy for 24 weeks, followed by the same anti-HER2 monotherapy until progression. Stratification was by prior (neo)adjuvant anti-HER2 therapy, prior (neo)adjuvant taxane, planned taxane, and liver metastases. The primary end point was intention-to-treat (ITT) progression-free survival (PFS), defined as time from random assignment to progression by RECIST (version 1.0) criteria, or death for patients with locally assessed HER2-positive tumors. The primary test statistic was a stratified log-rank test for noninferiority. PFS was also assessed for patients with centrally confirmed HER2-positive tumors. From July 17, 2008, to December 1, 2011, 652 patients were accrued from 21 countries, resulting in 537 patients with centrally confirmed HER2-positive tumors. Median follow-up was 21.5 months. Median ITT PFS was 9.0 months with lapatinib and 11.3 months with trastuzumab. By ITT analysis, PFS was inferior for lapatinib compared with...Continue Reading

References

Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OsobaJ Pater
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L SpectorSarah Bacus
Oct 21, 2005·The New England Journal of Medicine·Harold J Burstein
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas RobertDennis Slamon
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMichael F Press
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Apr 30, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodS H Giordano
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 25, 2011·Journal of Environmental Monitoring : JEM·Sandra N Correa-TorresSamuel P Hernández-Rivera
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Jan 20, 2012·The Lancet Oncology·Michael UntchUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zhongzhen GuanHenry Gomez

❮ Previous
Next ❯

Citations

Sep 1, 2015·Current Oncology Reports·Eleonora Teplinsky, Francisco J Esteva
Jun 5, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Thomas AparicioElena Paillaud
Jan 30, 2016·The Lancet Oncology·Ian E Krop
Aug 16, 2016·The Breast : Official Journal of the European Society of Mastology·Abraham Hernández-BlanquisettPaul Goss
Jul 15, 2016·The New England Journal of Medicine·John W ParkUNKNOWN I-SPY 2 Investigators
Dec 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yelena Y Janjigian
Dec 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W Sledge
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U Lin
Apr 8, 2017·Expert Opinion on Investigational Drugs·James N GersonIgor Astsaturov
Jun 27, 2017·Expert Review of Anticancer Therapy·Isabel EchavarriaMiguel Martin
Jul 12, 2017·Expert Opinion on Drug Safety·Samuel MartelEvandro De Azambuja
Dec 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E L Korn, B Freidlin
Aug 22, 2017·Breast Cancer Research and Treatment·Hye Duck Choi, Min Jung Chang
Sep 18, 2017·Clinical & Experimental Metastasis·Joo Yeon Nam, Barbara J O'Brien
Mar 5, 2016·American Journal of Therapeutics·XiongWen YangYingZhang Cheng
Jul 29, 2018·Genome Medicine·Sohini SenguptaLi Ding
Jan 9, 2019·Journal of Comparative Effectiveness Research·Tine GeldofIsabelle Huys
Mar 16, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara A Hurvitz
Aug 2, 2017·Nature Reviews. Clinical Oncology·Isabelle GingrasMartine Piccart-Gebhart
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Sara A HurvitzSara M Tolaney
Oct 7, 2017·Current Opinion in Oncology·Joseph GligorovVladimir Todorovic
Apr 10, 2020·Future Oncology·Alexandra S ZimmerPatricia S Steeg
Aug 16, 2016·Oncotarget·Ah-Rong NamYung-Jue Bang
Mar 27, 2019·Therapeutic Advances in Medical Oncology·Sonia Pernas, Sara M Tolaney
Nov 19, 2019·Frontiers in Oncology·Ana Godoy-OrtizEmilio Alba
Jun 17, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J GaviláA Llombart-Cussac

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andrew M WardleyAntonio Antón Torres
© 2021 Meta ULC. All rights reserved